Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women.

Background-The genetic background of hereditary hemochromatosis (HH) is homozygosity for a cysteine-to-tyrosine transition at position 282 in the HFE gene. Heterozygosity for HH is associated with moderately increased iron levels and could be a risk factor for cardiovascular death. Methods and Results-We studied the relation between HH heterozygosity and cardiovascular death in a cohort study among 12 239 women 51 to 69 years of age residing in Utrecht, the Netherlands. Women were followed for 16 to 18 years (182 976 follow-up years). The allele prevalence of the HH gene in the reference group was 4.0 (95% CI 2.9 to 5.4). The mortality rate ratios for HH heterozygotes compared with wild types was 1.5 (95% CI 0.9 to 2.5) for myocardial infarction (n=242), 2.4 (95% CI 1.3 to 3. 5) for cerebrovascular disease (n=118), and 1.6 (95% CI 1.1 to 2.4) for total cardiovascular disease (n=530). The population-attributable risks of HH heterozygosity for myocardial infarction and cerebrovascular and total cardiovascular death were 3. 3%, 8.8%, and 4.0%, respectively. In addition, we found evidence for effect modification by hypertension and smoking. Conclusions-We found important evidence that inherited variation in iron metabolism is involved in cardiovascular death in postmenopausal women, especially in women already carrying classic risk factors.

[1]  M. Wessling-Resnick.  Iron transport. , 2000, Annual review of nutrition.

[2]  T. Lakka,et al.  Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland. , 1999, Circulation.

[3]  F. Rosendaal.  Venous thrombosis: a multicausal disease , 1999, The Lancet.

[4]  H. Clevers,et al.  Defective iron homeostasis in β2-microglobulin knockout mice recapitulates hereditary hemochromatosis in man , 1997 .

[5]  H. Clevers,et al.  Mutations of the hereditary hemochromatosis candidate gene HLA-H in porphyria cutanea tarda. , 1997, The New England journal of medicine.

[6]  M. Worwood,et al.  Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda , 1997, The Lancet.

[7]  L. Jorde,et al.  Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. , 1996, The New England journal of medicine.

[8]  H. Clevers,et al.  Defective iron homeostasis in beta 2-microglobulin knockout mice recapitulates hereditary hemochromatosis in man , 1996, The Journal of experimental medicine.

[9]  M. C. Ellis,et al.  A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis , 1996, Nature Genetics.

[10]  R. Baynes.  Assessment of iron status. , 1996, Clinical biochemistry.

[11]  D. Williamson,et al.  Body iron stores and the risk of coronary heart disease. , 1994, The New England journal of medicine.

[12]  D. Leake,et al.  Iron released from transferrin at acidic pH can catalyse the oxidation of low density lipoprotein , 1994, FEBS letters.

[13]  L. Hurley,et al.  Iron stores are not associated with acute myocardial infarction. , 1994, Circulation.

[14]  H. Morrison,et al.  Serum iron and risk of fatal acute myocardial infarction. , 1994, Epidemiology.

[15]  M. Pippard,et al.  Iron Metabolism in Health and Disease , 1994 .

[16]  G. H. Frey,et al.  Serum ferritin and myocardial infarct. , 1994, The West Virginia medical journal.

[17]  G. Thorgeirsson,et al.  Low iron-binding capacity as a risk factor for myocardial infarction. , 1994, Circulation.

[18]  B. Halliwell,et al.  The role of oxygen radicals in human disease, with particular reference to the vascular system. , 1993, Haemostasis.

[19]  Heikki Korpela,et al.  High Stored Iron Levels Are Associated With Excess Risk of Myocardial Infarction in Eastern Finnish Men , 1992, Circulation.

[20]  J. Sullivan.  The iron paradigm of ischemic heart disease. , 1989, American heart journal.

[21]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[22]  M. Wheby,et al.  Hemochromatosis heterozygotes may have significant iron overload when they also have hereditary spherocytosis. , 1986, The American journal of the medical sciences.

[23]  J. Gutteridge.  Iron promoters of the Fenton reaction and lipid peroxidation can be released from haemoglobin by peroxides , 1986, FEBS letters.

[24]  E. A. Baanders-van Halewijn,et al.  The DOM project for the early detection of breast cancer, Utrecht, The Netherlands. , 1984, Journal of chronic diseases.

[25]  J. Sullivan.  IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK , 1981, The Lancet.

[26]  P. Mackowiak,et al.  Oyster-associated hepatitis: lessons from the Louisiana experience. , 1976, American journal of epidemiology.

[27]  O. Miettinen,et al.  Estimability and estimation in case-referent studies. , 1976, American journal of epidemiology.

[28]  J. Cook,et al.  Evaluation of the iron status of a population. , 1976, Blood.

[29]  M. Graffar.  [Modern epidemiology]. , 1971, Bruxelles medical.

[30]  H. L. Le Roy,et al.  Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability; Vol. IV , 1969 .

[31]  P. J. Huber.  The behavior of maximum likelihood estimates under nonstandard conditions , 1967 .

[32]  S. Boyer.  Papers on human genetics , 1963 .

[33]  B. Woolf.  ON ESTIMATING THE RELATION BETWEEN BLOOD GROUP AND DISEASE , 1955, Annals of human genetics.

[34]  G. Hardy.  MENDELIAN PROPORTIONS IN A MIXED POPULATION. , 1908 .